{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:18Z","timestamp":1792831038488,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110662","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:13:15Z","timestamp":1792105995000},"page":"110662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation"],"prefix":"10.1016","volume":"183","author":[{"given":"Shuai","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong-hui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-jin","family":"wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-han","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-meng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110662_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110662_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110662_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-026-03977-4","article-title":"A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors","volume":"27","author":"Oh","year":"2026","journal-title":"Genome Biol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0030","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110662_bb0035","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of Lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung Cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0040","first-page":"330","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bioorg.2026.110662_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110662_bb0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0055","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110662_bb0060","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/14737140.2023.2265566","article-title":"Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure","volume":"23","author":"Fukuda","year":"2023","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.110662_bb0065","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110662_bb0070","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0075","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0080","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110662_bb0085","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs Crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0090","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line Lorlatinib or Crizotinib in advanced ALK-positive lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110662_bb0095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for Lorlatinib-resistant compound ALK mutations in ALK-positive lung Cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110662_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115477","article-title":"Recent advances in the development of dual ALK\/ROS1 inhibitors for non-small cell lung cancer therapy","volume":"257","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115719","article-title":"Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants","volume":"28","author":"Zhu","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115715","article-title":"Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations","volume":"28","author":"Cao","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300416","article-title":"Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors","volume":"356","author":"Liu","year":"2023","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2026.110662_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108416","article-title":"Novel ALK inhibitors containing DAAP fragments: rational drug design and anti-tumor activity research","volume":"160","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117835","article-title":"Discovery of an ALK degrader for lorlatinib-resistant compound mutations","volume":"296","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0130","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1021\/acs.jmedchem.9b00446","article-title":"Drug discovery targeting anaplastic lymphoma kinase (ALK)","volume":"62","author":"Kong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0135","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.jmedchem.0c01707","article-title":"Targeting cysteine located outside the active site: An effective strategy for covalent ALKi design","volume":"64","author":"Yan","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118915","article-title":"Design, synthesis and biological evaluation of selective inhibitors against the L858R\/T790M\/C797S mutant EGFR kinase based on the scaffold of brigatinib","volume":"314","author":"Ding","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117146","article-title":"Synthesis of novel deuterated EGFR\/ALK dual-target inhibitors and their activity against non-small cell lung cancer","volume":"283","author":"Nie","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114626","article-title":"Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors","volume":"241","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0155","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110662_bb0160","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1021\/acs.jmedchem.2c01864","article-title":"Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions","volume":"66","author":"Gao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0165","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1021\/acs.jmedchem.1c00270","article-title":"Development of Alectinib-based PROTACs as novel potent degraders of anaplastic lymphoma kinase (ALK)","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0170","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1021\/acs.jmedchem.4c00208","article-title":"Distinct amino acid-based PROTACs target oncogenic kinases for degradation in non-small cell lung Cancer (NSCLC)","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0175","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1021\/acs.jmedchem.3c02340","article-title":"Novel amphiphilic PROTAC with enhanced pharmacokinetic properties for ALK protein degradation","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0180","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1021\/acs.jmedchem.1c00373","article-title":"Discovery of a Brigatinib degrader SIAIS164018 with destroying metastasis-related Oncoproteins and a reshuffling Kinome profile","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118387","article-title":"Design, synthesis, and biological evaluation of novel PROTACs based on unnatural dipeptide CRBN ligands","volume":"303","author":"Huang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116827","article-title":"Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers","volume":"279","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0195","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1021\/acs.jmedchem.4c00537","article-title":"Natural product-inspired dopamine receptor ligands","volume":"67","author":"Dorogan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2018.12.007","article-title":"Natural product derived privileged scaffolds in drug discovery","volume":"52","author":"Davison","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1172939","article-title":"Antitumor effects and potential mechanisms of aconitine based on preclinical studies: an updated systematic review and meta-analysis","volume":"14","author":"Xiang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115270","article-title":"Aconitine: a review of its pharmacokinetics, pharmacology, toxicology and detoxification","volume":"293","author":"Gao","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2026.110662_bb0215","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/med.21777","article-title":"Cardiac efficacy and toxicity of aconitine: a new frontier for the ancient poison","volume":"41","author":"Zhou","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110662_bb0220","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1021\/acs.chemrev.8b00504","article-title":"Structural simplification of natural products","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110662_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109360","article-title":"Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification","volume":"168","author":"Guo","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112988","article-title":"2-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: simplification and modification of aconitine scaffold for the discovery of novel anticancer agents","volume":"210","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117895","article-title":"Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0240","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110662_bb0245","doi-asserted-by":"crossref","first-page":"7848","DOI":"10.1016\/j.tet.2012.07.028","article-title":"Novel chiral bridged azepanes: stereoselective ring expansion of 2-azanorbornan-3-yl methanols","volume":"68","author":"Wojaczy\u0144ska","year":"2012","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2026.110662_bb0250","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1039\/b204677f","article-title":"Stereoselective and regioselective synthesis of azepane and azepine derivatives via piperidine ring expansion","author":"Chong","year":"2002","journal-title":"J. Chem. Soc., Perkin Trans. 1"},{"key":"10.1016\/j.bioorg.2026.110662_bb0255","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/pro.3997","article-title":"Templates for writing PyMOL scripts","volume":"30","author":"Mooers","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2026.110662_bb0260","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"van der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0265","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110662_bb0270","doi-asserted-by":"crossref","first-page":"10096","DOI":"10.1063\/1.1808117","article-title":"A modified TIP3P water potential for simulation with Ewald summation","volume":"121","author":"Price","year":"2004","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.110662_bb0275","doi-asserted-by":"crossref","DOI":"10.1063\/5.0040966","article-title":"A compression strategy for particle mesh Ewald theory","volume":"154","author":"Simmonett","year":"2021","journal-title":"J. Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:57:28Z","timestamp":1792828648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S0045206826011983"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110662","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110662"}}